SecBot SecBot
8-K ·Filed Mar 3, 2026

PLRX

PLIANT THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed8mo ago SEC0001746473-26-000024
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor for any unsolicited takeover interest or activist activity, as the extended rights agreement gives the board more time to respond. The move suggests management wants to maintain control flexibility in a potentially volatile biotech M&A environment.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.29
T+0 close · Mar 3, 2026 · via day close
Latest settled
−3.10%
T+60 · $1.25
Vs SPY
−13.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 4 $1.29entry
  2. T+1 · 9mo ago 0.00%α +0.57% · $1.29
  3. T+5 · 8mo ago +3.10%α +4.43% · $1.33
  4. T+20 · 8mo ago +2.33%α +6.74% · $1.32
  5. T+60 · 6mo ago −3.10%α −13.19% · $1.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pliant Therapeutics extended the expiration date of its shareholder rights agreement from March 11, 2026 to March 11, 2027. The amendment is designed to prevent coercive takeover attempts by requiring potential acquirers to negotiate with the board, but was not made in response to any specific offer.

Key Facts

  • Pliant Therapeutics extended the expiration of its shareholder rights agreement by one year, from March 11, 2026 to March 11, 2027
  • The rights agreement allows the board to delay or prevent unsolicited takeover attempts
  • The amendment was not made in response to any specific takeover offer
  • The rights may still be redeemed, exchanged, or terminated earlier under existing terms

Financial Impact

No direct financial impact, this is a corporate governance measure

governancetakeover defenseshareholder rights

Risk Factors

  • Could deter potential acquirers if seen as entrenching management
  • May face shareholder opposition if perceived as anti-takeover without clear strategic rationale

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001746473-26-000024
Document: pliant-rightsagreementamen.htm0001746473-26-000024
Document: 0001746473-26-000024-index-headers.html0001746473-26-000024
Document: 0001746473-26-000024-index.html0001746473-26-000024
Document: 0001746473-26-000024.txt0001746473-26-000024

Track record

8 reports on PLRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +11.02% at T+60 after the May 11, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
  2. Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
  3. May 11, 202627w ago 8-K Neutral 4/10 No price data
  4. May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
  5. Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
  6. Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
  7. Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
  8. Mar 3, 202636w ago 8-K Neutral 3/10 Viewing Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026